Ateneo - UPO

The course will cover the main lymphoproliferative diseases from the diagnostic, prognostic and therapeutic point of view. The course will also focus on the research in haematology. For this purpose, clinical trials will be analysed, new therapeutic possibilities with new monoclonal antibodies and with new biological drugs will be presented, and the concept of "benefit sharing" will be introduced.

Giuliani N, Olivieri A. EMATOLOGIA. Idelson-Gnocchi, 2020

The aim of the course is to render the student able to know, interpret and analyse the main hemato-oncological topics of the course that are relevant for a Physician, with a critical attitude, as requested by the Dublin descriptor 3. Specific aims are: a) know the pathophysiology and clinical picture of hemato-oncological diseases toward an appropriate clinical reasoning; b) bei able to critically interpret clinical and lab findings of hemato-oncological disorders, in order to formulate a correct diagnostic workup and an appropriate management of the patient

Knowledge of the contents of the propedeutical courses of the program

A) Taught (frontal) classes with slide presentations available on the UPO DIR website (https://www.dir.uniupo.it/); B) Self-test MCQs available on the DIR website (https://www.dir.uniupo.it/) after each class; C) Interpretation and presentation of clinical cases and lab findings

Internship: discussion of clinical cases and interpretation of the main physical and lab findings of hematological interest

Students with physical disabilities, Learning Disabilities or Special Education Needs can request
specific services and tools via the
, consulting the University webpage: https://www.uniupo.it/en/services/services-
students-physical-or-learning-disabilities
Students with disabilities, learning disabilities or special education needs, once they have contacted the University Staff, can refer to the tutor in charge of the course to define the examination
modalities, concerning academic aspects.

The exam will be in the context of the Integrated Course of which the Hematology Oncology course is part. The exam of Hematology Oncology will be based on 10 MCQs (5 possible answers, of which only 1 is correct), on the topics taught during classes. Examples of the MCQs are on the UPO DIR

A. GENERAL CONCEPTS OF LYMPHOID NEOPLASIA
A1. Histogenesis of lymphoid neoplasia
A2. Molecular pathology of lymphoid neoplasia
A3. Methodology of classification of lymphoid neoplasia
A4. Lab and imaging diagnostics of lymphoid neoplasia
A5. Signs and symptoms of lymphoid neoplasia

B. MAIN LYMPHOID NEOPLASMS
B1. Indolent and aggressive non-Hodgkin lymphomas
B2. Hodgkin lymphoma
B3. Monoclonal B cell lymphocytosis and chronic lymphocytic leukemia
B4. Hairy cell leukemia
B5. Monoclonal gamopathiesi: MGUS, multiple myeloma and other plasma cell neoplasms
B6. Acute lymphoblastic leukemia

C. NOVEL THERAPEUTIC STRATEGIES FOR LYMPHOID NEOPLASIA
C1. Immunotherapy
C2. Cell therapies
C3. Precision medicine applied to lymphoid neoplasia

D. Clinical research in Hematology
D1. Phase 1, 2, and 3 clinical trials in hematoncology
D2. “Benefit sharing” in hematoncology and ethical implicazioni of globalized clinical research

At the end of the course, the student will be able to understand the pathophysiology, the diagnosis and the main therapeutic armamentarium of lymphoid malignancies. The student will also appreciate, from a precision medicine perspective, the use of molecular diagnostics for choosing the best therapeutic strategy for each patient.